Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Huanyu Biological: Pro-101-1 Phase III clinical trial for the treatment of deep second-degree burns has enrolled the first patient.
Huansheng Biological announces that the company’s Phase IIIa clinical trial of Pro-101-1, developed for the treatment of deep second-degree burns, has recently completed the enrollment of the first patient. Pro-101-1 is one of the company’s core products. This clinical trial is a randomized, double-blind, placebo-controlled study aimed at further evaluating the efficacy and safety of recombinant human platelet-derived growth factor (rhPDGF-BB) gel in treating deep second-degree burn wounds, and to provide key parameters for the design of subsequent Phase IIIb clinical trials among a large number of enrolled subjects. The completion of the first patient enrollment in this Phase IIIa clinical trial of Pro-101-1 marks another significant R&D advancement for the company in the field of burn and scald treatment.